Treatment With Anti-vascular Endothelial Growth Factor in Patients With Branch Retinal Vein Occlusion: 5 Years of Clinical Experience

Trial Profile

Treatment With Anti-vascular Endothelial Growth Factor in Patients With Branch Retinal Vein Occlusion: 5 Years of Clinical Experience

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
  • Indications Retinal oedema; Retinal vein occlusion
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top